Price
$12.53
Increased by 0.00%
Dollar Volume
876.73 K
ADR%
3.49
Earnings Report Date (estimate)
Mar 15, 23 (-0.66)
Market Cap.
305.67 M
Shares Float
15.64 M
Shares Outstanding
24.40 M
Beta
0.00
Price / Earnings
2.60
BPR
131.39
20D Range
12.00 13.28
50D Range
11.80 13.60
200D Range
11.00 17.27
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 9, 22 -0.68
Increased by +92.58%
-0.74
Increased by +8.11%
Aug 10, 22 -0.87
Decreased by -866.67%
-0.75
Decreased by -16.00%
May 12, 22 -0.66
Decreased by -633.33%
-0.71
Increased by +7.04%
Mar 17, 22 -0.77
Decreased by -670.00%
-0.98
Increased by +21.43%
Nov 10, 21 -9.17
Decreased by -7.54 K%
-0.66
Decreased by -1.29 K%
Aug 11, 21 -0.09
Increased by +18.18%
-0.40
Increased by +77.50%
May 17, 21 -0.09
Increased by +18.18%
-0.09
Mar 11, 21 -0.10
Increased by +28.57%
-0.13
Increased by +23.08%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 4.25 M
Increased by +N/A%
-14.47 M
Increased by +83.38%
Decreased by -340.97%
Decreased by N/A%
Jun 30, 22 3.44 M
Increased by +N/A%
-18.27 M
Decreased by -314.46%
Decreased by -531.54%
Decreased by N/A%
Mar 31, 22 2.31 M
Increased by +N/A%
-13.86 M
Decreased by -211.97%
Decreased by -600.65%
Decreased by N/A%
Dec 31, 21 1.00 M
Increased by +6.67 B%
-15.99 M
Decreased by -238.94%
Decreased by -1.60 K%
Increased by +100.00%
Sep 30, 21 0.00
Decreased by N/A%
-87.09 M
Decreased by -1.66 K%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by -100.00%
-4.41 M
Decreased by -147.52%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-4.44 M
Decreased by -13.35%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.01
Increased by +N/A%
-4.72 M
Decreased by -6.11%
Decreased by -31.45 B%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.